Search results
Results from the WOW.Com Content Network
Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in US market. Nialamide: 1974 UK, US Hepatotoxicity, drug intereaction. [3] Nikethamide: 1988 multiple markets CNS Stimulation. [3] Nitrefazole: 1984 Germany Hepatic and hematologic toxicity. [3] Nomifensine: 1981 ...
Download as PDF; Printable version ... Following is a list of antipsychotics, sorted by class. Antipsychotics. Antipsychotics by class Generic name Brand names
Montelukast is in the leukotriene receptor antagonist family of medications. [6] It works by blocking the action of leukotriene D4 in the lungs resulting in decreased inflammation and relaxation of smooth muscle. [6] Montelukast was approved for medical use in the United States in 1998. [6] It is available as a generic medication. [8]
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs , ranked by sales.
A category for drugs withdrawn from the market after marketing commenced for any reason (voluntarily or involuntarily). For drug candidates that were abandoned prior to being marketed due to side effects, lack of efficacy, superior competitors, or other reasons, see Category:Abandoned drugs
Medication discontinuation is the ceasing of a medication treatment for a patient by either the clinician or the patient themself. [1] [2] When initiated by the clinician, it is known as deprescribing. [3] Medication discontinuation is an important medical practice that may be motivated by a number of reasons: [4] [3] Reducing polypharmacy